EngeneIC is a biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of chemotherapeutics and functional nucleic acids in cancer. The EDV™ is a first-in-class Cyto-Immunotherapy platform.
Headquarters:
Australia
Company Type:
SME
Company size:
11-50 Employees
Year Founded:
2001 (24 years)
Address:
11 JULIUS AVENUE; LEVEL 4; NORTH RYDE, NEW SOUTH WALES 2113, AU
LOW
spending power
